Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis - PR Newswire

AI Briefing

• – Celosia Therapeutics initiates Phase 1b clinical trial for CTx1000 in ALS.
• – The trial aims to evaluate the safety and efficacy of CTx1000 in patients with amyotrophic lateral sclerosis.
• – Celosia Therapeutics is a biotechnology company focused on developing innovative therapies for neurological disorders.